Research Areas
In ths section, by far, most Axon Ligands™ are categorized as research tools that find their application in cell signaling and oncology. Targeting a multitude of specific enzymes and receptors, they either stimulate or block particular cellular signaling pathways that are implicated in various kinds of cancer. Naturally, all products in this section can also be found by their specific biological targets as listed in the sections of enzymes, receptors, transcription factors, proteins and/or signaling pathways. Besides the comprehensive set of compounds that targe cell signaling and oncology, selections of Axon Ligands™ have also been made for other research area's such as cardiovascular diseases, angiogenisis, epigenetics, stem cell research, among many others.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 2138 | ZCL 278 | Cdc42 GTPase inhibitor, targeting Cdc42–ITSN interaction | €105.00 | |
| 2816 | WX-132-18B | Tubulin-polymerization inhibitor targeting the colchicine site | €115.00 | |
| 1804 | Wiskostatin | Inhibitor of neural Wiskott-Aldrich syndrome protein (N-WASP) | €105.00 | |
| 2073 | UK 383367 | Inhibitor of bone morphogenetic protein 1 (BMP-1, aka PCP) | €80.00 | |
| 2111 | UK 356618 | Potent MMP-3 (aka Stromelysin-1) inhibitor | €90.00 | |
| 2398 | Suprafenacine | Destabilizer of microtubules that causes cell cycle arrest in the G2/M phase | €110.00 | |
| 2815 | SP-6-27 | Microtubule inhibitor | €125.00 | |
| 2370 | SB-3CT | Potent and selective inhibitor of Gelatinases MMP-2 and MMP-9 | €125.00 | |
| 3083 | PVHD121 | Microtubule inhibitor | €120.00 | |
| 2328 | PTIQ | Neuroprotectant with attenuating effects on MMP-3 expression | €125.00 | |
| 1181 | PF 00356231 | MMP-12 inhibitor | €135.00 | |
| 1271 | PD 166793 | MMP inhibitor | €90.00 | |
| 2393 | NSC 756093 | Potent in vitro inhibitor of GBP1:PIM1 interaction | €125.00 | |
| 2162 | NSC 405020 | MT1-MMP inhibitor specifically targeting PEX-domain. | €85.00 | |
| 1578 | NSC 23766 | Rac1 inhibitor | €110.00 | |